123 related articles for article (PubMed ID: 35662501)
1. Identification of potential biomarkers and novel therapeutic targets through genomic analysis of small cell bladder carcinoma and associated clinical outcomes.
Burgess EF; Sanders JA; Livasy C; Symanowski J; Gatalica Z; Steuerwald NM; Arguello D; Brouwer CR; Korn WM; Grigg CM; Zhu J; Matulay JT; Clark PE; Heath EI; Raghavan D
Urol Oncol; 2022 Aug; 40(8):383.e1-383.e10. PubMed ID: 35662501
[TBL] [Abstract][Full Text] [Related]
2. Urothelial Cancers with Small Cell Variant Histology Have Confirmed High Tumor Mutational Burden, Frequent TP53 and RB Mutations, and a Unique Gene Expression Profile.
Hoffman-Censits J; Choi W; Pal S; Trabulsi E; Kelly WK; Hahn NM; McConkey D; Comperat E; Matoso A; Cussenot O; Cancel-Tassin G; Fong MHY; Ross J; Madison R; Ali S
Eur Urol Oncol; 2021 Apr; 4(2):297-300. PubMed ID: 32061548
[TBL] [Abstract][Full Text] [Related]
3. Genomic predictors of survival in patients with high-grade urothelial carcinoma of the bladder.
Kim PH; Cha EK; Sfakianos JP; Iyer G; Zabor EC; Scott SN; Ostrovnaya I; Ramirez R; Sun A; Shah R; Yee AM; Reuter VE; Bajorin DF; Rosenberg JE; Schultz N; Berger MF; Al-Ahmadie HA; Solit DB; Bochner BH
Eur Urol; 2015 Feb; 67(2):198-201. PubMed ID: 25092538
[TBL] [Abstract][Full Text] [Related]
4. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
5. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target.
Koshkin VS; Garcia JA; Reynolds J; Elson P; Magi-Galluzzi C; McKenney JK; Isse K; Bishop E; Saunders LR; Balyimez A; Rashid S; Hu M; Stephenson AJ; Fergany AF; Lee BH; Haber GP; Dowlati A; Gilligan T; Ornstein MC; Rini BI; Abazeed ME; Mian OY; Grivas P
Clin Cancer Res; 2019 Jan; 25(1):210-221. PubMed ID: 30327311
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive genomic profiling of upper tract urothelial carcinoma and urothelial carcinoma of the bladder identifies distinct molecular characterizations with potential implications for targeted therapy & immunotherapy.
Tang Q; Zuo W; Wan C; Xiong S; Xu C; Yuan C; Sun Q; Zhou L; Li X
Front Immunol; 2022; 13():1097730. PubMed ID: 36818471
[TBL] [Abstract][Full Text] [Related]
7. Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Hamid AA; Gray KP; Shaw G; MacConaill LE; Evan C; Bernard B; Loda M; Corcoran NM; Van Allen EM; Choudhury AD; Sweeney CJ
Eur Urol; 2019 Jul; 76(1):89-97. PubMed ID: 30553611
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer.
Geredeli C; Artac M; Yildirim S; Inal A; Dede I; Guler T; Boruban MC; Koral L; Karaagac M; Zamani AG; Altinok T; Aribas O; Bozcuk H; Demirkazik A
Tumour Biol; 2015 Jun; 36(6):4279-85. PubMed ID: 25596702
[TBL] [Abstract][Full Text] [Related]
9. Comparison of clinicopathological characteristics, gene expression profiles, mutational analysis, and clinical outcomes of pure and mixed small-cell carcinoma of the bladder.
Parimi V; Choi W; Feng M; Fong M; Hoffman-Censits J; Kates M; Lombardo KA; Comperat E; McConkey DJ; Hahn NM; Esteves RS; Matoso A
Histopathology; 2023 Jun; 82(7):991-1002. PubMed ID: 36754853
[TBL] [Abstract][Full Text] [Related]
10. Genomic characterization of response to chemoradiation in urothelial bladder cancer.
Desai NB; Scott SN; Zabor EC; Cha EK; Hreiki J; Sfakianos JP; Ramirez R; Bagrodia A; Rosenberg JE; Bajorin DF; Berger MF; Bochner BH; Zelefsky MJ; Kollmeier MA; Ostrovnaya I; Al-Ahmadie HA; Solit DB; Iyer G
Cancer; 2016 Dec; 122(23):3715-3723. PubMed ID: 27479538
[TBL] [Abstract][Full Text] [Related]
11. Genomic Tumor Correlates of Clinical Outcomes Following Organ-Sparing Chemoradiation Therapy for Bladder Cancer.
Kamran SC; Zhou Y; Otani K; Drumm M; Otani Y; Wu S; Wu CL; Feldman AS; Wszolek M; Lee RJ; Saylor PJ; Lennerz J; Van Allen E; Willers H; Hong TS; Liu Y; Davicioni E; Gibb EA; Shipley WU; Mouw KW; Efstathiou JA; Miyamoto DT
Clin Cancer Res; 2023 Dec; 29(24):5116-5127. PubMed ID: 37870965
[TBL] [Abstract][Full Text] [Related]
12. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
13. Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2.
Posada JM; Yakirevich E; Kamat AM; Sood A; Jacob JM; Bratslavsky G; Grivas P; Spiess PE; Li R; Necchi A; Mega AE; Golijanin DJ; Pavlick D; Huang RSP; Lin D; Danziger N; Sokol ES; Sivakumar S; Ross JS; Cheng L
Mod Pathol; 2024 Mar; 37(3):100424. PubMed ID: 38219954
[TBL] [Abstract][Full Text] [Related]
14. Genomic alterations of plasma cell-free DNAs in small cell lung cancer and their clinical relevance.
Du M; Thompson J; Fisher H; Zhang P; Huang CC; Wang L
Lung Cancer; 2018 Jun; 120():113-121. PubMed ID: 29748005
[TBL] [Abstract][Full Text] [Related]
15. High aurora kinase expression identifies patients with muscle-invasive bladder cancer who have poor survival after neoadjuvant chemotherapy.
Burgess EF; Livasy C; Trufan S; Hartman A; Guerreri R; Naso C; Clark PE; Grigg C; Symanowski J; Raghavan D
Urol Oncol; 2019 Dec; 37(12):900-906. PubMed ID: 31597600
[TBL] [Abstract][Full Text] [Related]
16. Genomic Predictors of Good Outcome, Recurrence, or Progression in High-Grade T1 Non-Muscle-Invasive Bladder Cancer.
Bellmunt J; Kim J; Reardon B; Perera-Bel J; Orsola A; Rodriguez-Vida A; Wankowicz SA; Bowden M; Barletta JA; Morote J; de Torres I; Juanpere N; Lloreta-Trull J; Hernandez S; Mouw KW; Taplin ME; Cejas P; Long HW; Van Allen EM; Getz G; Kwiatkowski DJ
Cancer Res; 2020 Oct; 80(20):4476-4486. PubMed ID: 32868381
[TBL] [Abstract][Full Text] [Related]
17. Actionable genomic landscapes from a real-world cohort of urothelial carcinoma patients.
Gerald T; Margulis V; Meng X; Bagrodia A; Cole S; Qin Q; Call SG; Mauer E; Lotan Y; Woldu SL
Urol Oncol; 2023 Mar; 41(3):148.e17-148.e24. PubMed ID: 36653279
[TBL] [Abstract][Full Text] [Related]
18. POU2F3-positive small cell carcinoma of the bladder: A clinicopathologic analysis of 4 cases and literature review.
Cai Z; Cheng X; Liao S; Zou W; Li L; Liu F; Huang W
Pathol Res Pract; 2024 May; 257():155296. PubMed ID: 38615507
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of the feasibility and prognostic value of circulating tumor DNA in detecting gene mutations in small cell lung cancer].
Jin Y; Chen YM; Hu X; Tang HR; Yu XM; Fan Y; Xu YJ; Xu HM; Li PS; Li Q; Chang LP; Guan YF; Chen M
Zhonghua Yi Xue Za Zhi; 2020 Dec; 100(45):3614-3621. PubMed ID: 33333686
[No Abstract] [Full Text] [Related]
20. Impact of nucleotide excision repair ERCC2 and base excision repair APEX1 genes polymorphism and its association with recurrence after adjuvant BCG immunotherapy in bladder cancer patients of North India.
Gangawar R; Ahirwar D; Mandhani A; Mittal RD
Med Oncol; 2010 Jun; 27(2):159-66. PubMed ID: 19242824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
